Broadview and Panakes on CorFlow financing round: the advisors

Kellerhals Carrard advised Broadview Ventures and Panakes Partners in leading the EUR 44 million Series B financing round of CorFlow Therapeutics, advised by Walder Wyss. This round also includes participation from Merieux Equity Partners, Laerdal Million Lives Fund, Wellington Partners, M&L INVESTMENTS, L.C., Unorthodox Ventures, Kofa Healthcare and Monte Carlo Capital, with continued support from 415 Capital, CorFlow’s initial VC investor and largest shareholder.

Kellerhals Carrard team

The Kellerhals Carrard team was co-led by VC/M&A partner Karim Maizar (pictured left) and VC/M&A senior associate Umberto Milano (pictured right) and further included Céline Schmid (senior associate, employment), Vera Vallone (associate, IP) and Melissa Wiss (paralegal).

Walder Wyss team

Walder Wyss team was led by corporate / M&A partner Alex Nikitine (pictured below) and further included Dominik Aerni (counsel, corporate/M&A), Viktoriya Chernaya (associate, corporate/M&A), Maurus Winzap (partner, tax), Janine Corti (counsel, tax) and Viviana Montorfano (trainee, corporate/M&A).

About the founding

The Series B will fund the MOCA II (MVO with CoFITM System Assessment II) pivotal study intended to gain US market clearance. The trial will run in the US and Europe and aims to validate CorFlow’s CoFl system to diagnose microvascular obstruction (“MVO”) in heart attack patients immediately following stent implantation. Additionally, it will fund an adaptive platform therapy study evaluating treatment effects of therapeutic agents delivered locally through the CoFl system on heart attack patients diagnosed with MVO.

The funding will also support a novel adaptive platform therapy trial in Europe evaluating whether localized delivery of therapeutics to the microvasculature immediately following stent implantation can improve outcomes in patients diagnosed with MVO. Led by Dr. Giovanni Luigi De Maria (Oxford University Hospitals Trust, UK) and Professor Colin Berry (University of Glasgow and NHS Golden Jubilee National Hospital, UK), this European RCT will assess the effects of several therapeutic agents with both clinical and imaging measures up to six months.

Concurrent with the financing, David Prim of Broadview Ventures, Barbara Castellano of Panakes Partners, Yoann Bonnamour of Merieux Equity Partners, and Rhiya Pau of Laerdal Million Lives Fund have joined the CorFlow Board of Directors.

CorFlow

Headquartered in Baar, Switzerland, with offices in Italy, and founded in 2016 by Dr. Rob Schwartz, Dr. Martin Rothman and Jon Hoem. CorFlow aspires to be the leader in diagnostic and therapeutic solutions for restoring healthy microvascular blood flow anywhere in the human body where a critical need exists. Working in close partnership with scientists from the University of Bern, ETH Zurich and the University Hospital Zurich, in a collaboration funded by the Swiss Innovation Agency (Innosuisse), CorFlow continues to explore applications in and beyond the heart.